| 124.00 Delayed Data As of Feb 22 |  0.00 / 0.00%Today’s Change | 74.51 Today|||52-Week Range 124.74 | +7.16% Year-to-Date |
| Previous close | 124.00 |
| Today’s open | 122.73 |
| Day’s range | 122.65 - 124.74 |
| Volume | 19,574,004 |
| Average volume (3 months) | 6,027,912 |
| Market cap | $129.7B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +0.77% |
| Earnings growth (next 5 years) | +10.95% |
| Revenue growth (last year) | +7.36% |
| P/E ratio | 39.6 |
| Price/Sales | 4.87 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +0.99 | +1.32% |
| SNYSanofi | 0.00 | 0.00% |
| ABBVAbbVie | +1.27 | +1.61% |
| AZNAstraZeneca | +0.51 | +1.26% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $1.30 |
| Annual revenue (last year) | $24.6B |
| Annual profit (last year) | $3.2B |
| Net profit margin | 13.16% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer David A. Ricks |
Senior VP-Biotechnology & Autoimmunity Research Thomas F. Bumol |
Corporate headquarters Indianapolis, Indiana |
